Alnylam announces results from post hoc analyses of HELIOS-B Phase 3 study

Alnylam (ALNY) Pharmaceuticals announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA, an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, ATTR-CM, and the polyneuropathy of hereditary transthyretin-mediated amyloidosis, hATTR-PN, in adults. Data from cardiovascular magnetic resonance, CMR, and echocardiographic imaging as well as renal function analyses were presented at the American Heart Association, AHA, Scientific Sessions 2025 in New Orleans, Louisiana. Key Findings: Cardiovascular Magnetic Resonance and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters; In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received placebo; Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease